X Versus Placebo as Postoperative Adjuvant Treatment for Elder Breast Cancer
Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast cancer patients.
Breast Cancer
DRUG: Capecitabine|DRUG: Placebo
Disease-free survival, 5 years|Adverse event rate (CTCAE v. 3.0), 5 years
Overall survival, 5 years
Our study is a prospective, randomized phase II clinical trial, to compare the efficacy and safety profiles of single X versus placebo as adjuvant chemotherapy regimens for elder breast cancer patients.